Lovenox and Infusion site urticaria - a phase IV clinical study of FDA data

Summary:

Infusion site urticaria is reported only by a few people who take Lovenox.

The phase IV clinical study analyzes which people take Lovenox and have Infusion site urticaria. It is created by eHealthMe based on reports of 43,880 people who have side effects while taking Lovenox from the FDA, and is updated regularly.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Aug, 10, 2022

43,880 people reported to have side effects when taking Lovenox.
Among them, 5 people (0.01%) have Infusion site urticaria.


What is Lovenox?

Lovenox has active ingredients of enoxaparin sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 42,320 Lovenox users for its effectiveness, alternative drugs and more.

What is Infusion site urticaria?

Infusion site urticaria (rash of round, red welts on the skin at infusion site) is found to be associated with 260 drugs and 71 conditions by eHealthMe.

Number of Lovenox and Infusion site urticaria reports submitted per year:

Could Lovenox cause Infusion site urticaria?

Gender of people who have Infusion site urticaria when taking Lovenox *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Infusion site urticaria when taking Lovenox *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 20 %
  • 30-39: 0.0 %
  • 40-49: 60 %
  • 50-59: 20 %
  • 60+: 0.0 %

Common drugs people take besides Lovenox *:

  1. Zetia: 3 people, 60.00%
  2. Cytotec: 3 people, 60.00%
  3. Lisinopril: 3 people, 60.00%
  4. Zanaflex: 3 people, 60.00%
  5. Levemir: 3 people, 60.00%
  6. Lasix: 3 people, 60.00%
  7. Hydrochlorothiazide: 3 people, 60.00%
  8. Fenofibrate: 3 people, 60.00%
  9. Enoxaparin Sodium: 3 people, 60.00%
  10. Cymbalta: 3 people, 60.00%

Common side effects people have besides Infusion site urticaria *:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 60.00%
  2. Infusion Site Swelling: 3 people, 60.00%
  3. Cellulitis (infection under the skin): 3 people, 60.00%
  4. Infusion Site Reaction: 3 people, 60.00%
  5. Infusion Site Erythema (reddening of the skin at infusion site): 2 people, 40.00%
  6. Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 2 people, 40.00%
  7. Itching: 1 person, 20.00%
  8. Lung Infection: 1 person, 20.00%
  9. Malaise (a feeling of general discomfort or uneasiness): 1 person, 20.00%
  10. Respiratory Tract Infection: 1 person, 20.00%

Common conditions people have *:

  1. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 2 people, 40.00%
  2. Pneumonia: 1 person, 20.00%
  3. Asthma: 1 person, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lovenox and have Infusion site urticaria?

Check whether Infusion site urticaria is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Lovenox:

Infusion site urticaria treatments and more:

COVID vaccines that are related to Infusion site urticaria:

How severe was Infusion site urticaria and when was it recovered:

Expand to all the drugs that have ingredients of enoxaparin sodium:

All the drugs that are associated with Infusion site urticaria:

All the conditions that are associated with Infusion site urticaria:

How the study uses the data?

The study uses data from the FDA. It is based on enoxaparin sodium (the active ingredients of Lovenox) and Lovenox (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: